Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
Recent Content
- Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
- Plasmablastic myeloma transformation of light-chain multiple myeloma
- The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
- Dr Anderson on the FDA ODAC Decision Regarding Cilta-Cel in R/R Multiple Myeloma
- Implementing multi-level network meta-regression for time-to-event outcomes: A case study in relapsed refractory multiple myeloma
- Recent advances in the treatment and prevention of peripheral neuropathy after multiple myeloma treatment
- Results of Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma(MM) and Renal Impairment: A Retrospective Single-Center Study
- Seven-year Follow-up of India’s First Sequential Hematopoietic Stem Cell and Kidney Transplant for Multiple Myeloma
- Selenoprotein W engages in overactive osteoclast differentiation in multiple myeloma
- Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma